CRH Medical (NYSEAMERICAN:CRHM) Downgraded to Hold at Zacks Investment Research

Zacks Investment Research cut shares of CRH Medical (NYSEAMERICAN:CRHM) from a buy rating to a hold rating in a report released on Monday, January 15th.

According to Zacks, “CRH Medical Corporation offers products and services to physicians for the treatment of gastrointestinal diseases primarily in the United States. The company provides the CRH O’Regan System, a single use, disposable and hemorrhoid banding technology for treating hemorrhoid grades I – IV. It distributes the CRH O’Regan System, treatment protocols, operational and marketing expertise as a complete, turnkey package directly to physicians. The company utilizes Web-based platform to connect doctors with patients as well as educating its install base of physicians. It also offers anesthesia services. CRH Medical Corporation is headquartered in Vancouver, Canada. “

Separately, Morgan Stanley upgraded shares of CRH Medical from an equal weight rating to an overweight rating in a research note on Friday, November 17th. Four equities research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. The company has a consensus rating of Buy and an average price target of $6.00.

CRH Medical (CRHM) traded down $0.15 during trading hours on Monday, reaching $2.65. 276,709 shares of the company’s stock traded hands, compared to its average volume of 132,550. The stock has a market cap of $207.56, a P/E ratio of 37.86 and a beta of 1.10. CRH Medical has a 12 month low of $1.46 and a 12 month high of $9.25.

A number of large investors have recently bought and sold shares of the business. Advisor Group Inc. grew its holdings in shares of CRH Medical by 35.0% during the second quarter. Advisor Group Inc. now owns 36,177 shares of the company’s stock worth $206,000 after buying an additional 9,389 shares in the last quarter. Vanguard Group Inc. purchased a new stake in shares of CRH Medical during the second quarter worth $150,000. PDT Partners LLC grew its holdings in shares of CRH Medical by 176.4% during the second quarter. PDT Partners LLC now owns 50,162 shares of the company’s stock worth $285,000 after buying an additional 32,013 shares in the last quarter. TD Asset Management Inc. grew its holdings in shares of CRH Medical by 65.3% during the third quarter. TD Asset Management Inc. now owns 111,054 shares of the company’s stock worth $289,000 after buying an additional 43,851 shares in the last quarter. Finally, Stifel Financial Corp grew its holdings in shares of CRH Medical by 7.7% during the third quarter. Stifel Financial Corp now owns 1,665,839 shares of the company’s stock worth $4,332,000 after buying an additional 119,685 shares in the last quarter.

TRADEMARK VIOLATION NOTICE: “CRH Medical (NYSEAMERICAN:CRHM) Downgraded to Hold at Zacks Investment Research” was first posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this news story on another publication, it was stolen and reposted in violation of United States and international trademark and copyright law. The original version of this news story can be viewed at https://ledgergazette.com/2018/02/10/crh-medical-crhm-downgraded-by-zacks-investment-research.html.

CRH Medical Company Profile

CRH Medical Corporation is a Canada-based healthcare products and services company. The Company focused on providing physicians with services and products for the treatment of gastrointestinal diseases. The Company also provides anesthesiology services to gastroenterologists in the United States through its subsidiaries.

Get a free copy of the Zacks research report on CRH Medical (CRHM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for CRH Medical (NYSEAMERICAN:CRHM)

Receive News & Ratings for CRH Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRH Medical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply